All the news Showing 10 of 835 articlesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Coronavirus Will people with liver disease be prioritised for COVID-19 vaccination? Keith Alcorn / 19 January 2021 People with decompensated cirrhosis should be prioritised for COVID-19 vaccination and immunosuppressive treatment after a liver transplant should not be a barrier to vaccination, an international panel of liver experts has concluded. Their review ... Hepatitis C elimination What's needed to eliminate hepatitis C in people with HIV in Scotland? Keith Alcorn / 18 January 2021 To eliminate hepatitis C in people with HIV in Scotland, healthcare providers will need to reach people not on HIV treatment and step up testing for hepatitis C in people ... Access to medicines & diagnostics Public-sector hepatitis C treatment programmes expanding in lower- and middle-income countries Keith Alcorn / 08 January 2021 Public-sector hepatitis C treatment programmes have cured tens of thousands of people in lower- and lower-middle-income countries with the aid of low-cost direct-acting antivirals and diagnostics, a simplified approach to treatment and large-scale ... Experimental treatments for NASH/NAFLD Semaglutide alone or in combination regimens shows promise for NASH Liz Highleyman / 18 December 2020 Semaglutide, a medication approved to treat type 2 diabetes, increased the likelihood of improvement in non-alcoholic steatohepatitis (NASH) without worsening liver fibrosis, researchers reported at the AASLD virtual Liver Meeting. What's more, ... Experimental treatments for NASH/NAFLD Lanifibranor improves NASH in 24-week trial Keith Alcorn / 18 December 2020 Twenty-four weeks of treatment with lanifibranor, a drug designed to treat NASH, improved liver fibrosis in 42% of people treated in a phase 2b clinical trial, Professor Sven Francque of Antwerp ... Experimental treatments for NASH/NAFLD Efruxifermin improves liver fat and fibrosis in people with NASH Keith Alcorn / 15 December 2020 Efruxifermin reduced liver fat and improved liver inflammation and fibrosis in the majority of people with NASH who received it in a phase 2a trial but nausea and vomiting led 10% of ... Prisoners High hepatitis C cure rate achieved in New York prisons Keith Alcorn / 09 December 2020 Hepatitis C treatment in prisons can result in a high cure rate but people released from prison during treatment are less likely to be cured due to challenges in medication supply, continuity ... Antiviral therapy 2.5 million people in Africa need urgent hepatitis B treatment Keith Alcorn / 09 December 2020 Around 2.5 million people with hepatitis B in sub-Saharan Africa already have cirrhosis and need immediate antiviral treatment, a systematic review of published studies reports this month in the journal Liver International. Approximately ... Epidemiology Few countries will meet 2020 target for reducing viral hepatitis deaths Keith Alcorn / 24 November 2020 Around 1.1 million deaths were caused by viral hepatitis worldwide in 2019 and deaths due to hepatitis C are still rising despite the availability of direct-acting antiviral treatment, according to analyses of ... Antiviral therapy Some hepatitis B patients can safely stop antivirals Liz Highleyman / 24 November 2020 Many people who take nucleoside/nucleotide antivirals for chronic hepatitis B can safely discontinue treatment, although this usually does not lead to a cure, researchers reported last week at the AASLD virtual Liver Meeting. Nucleoside/nucleotide analogues such ... ← First12345...84Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Noticeboard Email bulletins News feeds